Xanomeline/ trospium chloride · Cobenfy
Small molecule
Evidence outlook
Approved: Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Alzheimer's Disease · Phase 3 · investigational in the USBipolar Disorder · Phase 3 · investigational in the US
Also approved (1)
- Schizophrenia in adults
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EMERGENT-2 NCT04659161 · Schizophrenia, Schizophrenia; Psychosis This was a randomized, triple-blind, placebo-controlled trial involving 252 participants, with 117 KarXT and 119 placebo participants included in the primary analysis. The clinical primary endpoint was met: PANSS total scores decreased more with KarXT than placebo at Week 5, with a least-squares mean difference of -9.6 points and p<0.0001. Registry: NCT04659161 | 3 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5) 2022-05-24 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6) | Reliable signal | link ↗ |
View 2 more trials
ARISE NCT05145413 · Schizophrenia This was a randomized, quadruple-blind, placebo-controlled trial involving 396 participants, with 197 assigned to KarXT and 199 to placebo. The primary clinical endpoint, change in PANSS total score at Week 6, was not statistically significant between groups (p=0.1115), so the trial provides well-controlled but inconclusive evidence of benefit. Registry: NCT05145413 | 3 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (Baseline to Week 6) 2025-03-19 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (Baseline to Week 6): KarXT -14.3 Score on a Scale (Standard Error 1.01) vs Placebo -12.2 Score on a Scale (Standard Error 0.98) | Partial signal | link ↗ |
EMERGENT-3 NCT04738123 · Schizophrenia Participants were randomly assigned to xanomeline-trospium or placebo, with participants, investigators and outcome assessors blinded, and the trial enrolled 256 people against a planned 246 based on a reported sample-size calculation. Xanomeline-trospium improved schizophrenia symptoms on the PANSS total score significantly more than placebo at week 5 (difference 8.4 points, 95% CI 4.3 to 12.4, P < .001). Registry: NCT04738123 | 3 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5) 2022-11-29 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (30)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Alzheimer's Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Xanomeline / Trospium Chloride (Cobenfy): this drug | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | not yet graded | No reviewed efficacy summary in this indication | |
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) | |
| Donepezil (Aricept) | Approved | Small molecule | Acetylcholinesterase | Partial signal | NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). | |
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed | |
| AR1001 | Phase 3 | Small molecule | PDE5 | Partial signal | NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed | |
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | Partial signal | No reviewed efficacy summary in this indication | |
| Brexpiprazole (Rexulti) | Phase 3 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90 NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03) | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | Partial signal | NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg). | |
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | Partial signal | NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73) NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309) | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level) | |
| Masupirdine | Phase 3 | Small molecule | Serotonin 5-HT6 receptor | Partial signal | NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed | |
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Traditional Chinese medicine (multi-component) | not yet graded | No reviewed efficacy summary in this indication | |
| Remlifanserin | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Remternetug | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Sodium Oligomannate | Phase 3 | Small molecule | Gut microbiome / neuroinflammation | Reliable signal | NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971 | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | Partial signal | NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed | |
| Tricaprilin | Phase 3 | Small molecule | Ketone-body metabolism | Partial signal | NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed | |
| Trontinemab | Phase 3 | Multispecific antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| AGB101 | Phase 2/3 | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A), low-dose | Partial signal | NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed | |
| Blarcamesine | Phase 2/3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | Partial signal | NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed | |
| Deramciclane | Phase 2/3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deraphan | Phase 2/3 | Small molecule | NMDA receptor / 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2/3 | Small molecule | 11-beta-HSD1 | Partial signal | NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65) | |
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | Weak signal | Featured results are safety only in this race | |
| Nivegacetor | Phase 2/3 | Undisclosed | Gamma-secretase (modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| PM012 | Phase 2/3 | Botanical | Traditional Chinese medicine (multi-component) | Partial signal | No reviewed efficacy summary in this indication | |
| T3D-959 | Phase 2/3 | Small molecule | PPAR delta/gamma | Partial signal | No reviewed efficacy summary in this indication | |
| 50561 | Phase 2 | Small molecule | RAC1 | Partial signal | No reviewed efficacy summary in this indication | |
| AADvac1 | Phase 2 | Vaccine | Tau | Weak signal | Featured results are safety only in this race | |
| ABvac40 | Phase 2 | Vaccine | Amyloid-beta (Aβx-40) | Partial signal | Featured results are non-efficacy and safety only in this race | |
| ACI-35.030 | Phase 2 | Vaccine | Tau | Partial signal | Featured results are safety only in this race | |
| AD04 | Phase 2 | Vaccine | Aluminium hydroxide (Alhydrogel) | not yet graded | No reviewed efficacy summary in this indication | |
| AstroStem | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. | |
| AV-1959R | Phase 2 | Vaccine | Amyloid-beta | Weak signal | Featured results are safety only in this race | |
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | Partial signal | NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed | |
| Betovumeline / Fesoterodine (ML-007C-MA) | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| BEY2153 | Phase 2 | Small molecule | APP/tau (translation) | Partial signal | No reviewed efficacy summary in this indication | |
| Cerebrolysin | Phase 2 | Peptide | Porcine brain-derived neuropeptide mixture (multi-target) | Partial signal | NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diranersen | Phase 2 | RNA / oligonucleotide | MAPT mRNA (RNAi/ASO) | Weak signal | NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed | |
| Edaravone (TTYP01) | Phase 2 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Enrupatinib | Phase 2 | Small molecule | CSF-1R | not yet graded | No reviewed efficacy summary in this indication | |
| HT-4253 | Phase 2 | Small molecule | LRRK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Laromestrocel (Lomecel-B) | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | Featured results are safety only in this race | |
| Lemborexant (Dayvigo) | Phase 2 | Small molecule | Orexin receptor (repositioned) | Partial signal | NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002). | |
| Leronlimab | Phase 2 | Monoclonal antibody | CCR5 co-receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LHP588 | Phase 2 | Small molecule | Gingipain | not yet graded | No reviewed efficacy summary in this indication | |
| Lifonebart (VHB937) | Phase 2 | Monoclonal antibody | TREM2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mivelsiran | Phase 2 | RNA / oligonucleotide | APP mRNA (RNAi) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-2214 | Phase 2 | Monoclonal antibody | Phospho-tau (pSer413) | Partial signal | Featured results are safety only in this race | |
| Moponetug | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| NTRX-07 | Phase 2 | Small molecule | CB2 receptor | Weak signal | Featured results are safety only in this race | |
| ONO-2020 | Phase 2 | Small molecule | Epigenetic regulation (target undisclosed) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegipanermin | Phase 2 | Biologic (subtype unspecified) | Soluble TNF (selective) | Partial signal | NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed | |
| PRI-002 | Phase 2 | Small molecule | Amyloid-beta-42 oligomerization | Partial signal | No reviewed efficacy summary in this indication | |
| RB-ADSC | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RO7269162 | Phase 2 | Small molecule | Gamma-secretase | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448851 | Phase 2 | Small molecule | TREM2 | Weak signal | Featured results are safety only in this race | |
| Seltorexant | Phase 2 | Small molecule | Orexin-2 receptor (OX2R) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1707 | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2 | Small molecule | Dendritic spine density | not yet graded | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | Weak signal | Featured results are safety only in this race | |
| Emraclidine | Phase 1 | Small molecule | Muscarinic M4 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LY03017 | Phase 1 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LY03020 | Phase 1 | Small molecule | 5-HT2C/TAAR1 receptor | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 65 furthest-along competitors are listed; 57 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(25 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cobenfy (Xanomeline/trospium chloride) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
November 2026 (2)
December 2026 (1)
What to watch
2027 (6)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (2)
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (7)
February 2028 (1)
What to watch
June 2028 (1)
What to watch
September 2028 (3)
What to watch
What to watch
What to watch
2029 (5)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (2)
December 2029 (1)
What to watch
2030 (2)
March 2030 (1)
What to watch
September 2030 (1)
What to watch
2031 (1)
December 2031 (1)
What to watch
2032 (1)
June 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent